Vir Biotechnology, Inc. — Director's Dealing 2021

Dec 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-12-14

Reporting Person: Virgin Herbert (EVP, Research & CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-14	Common Stock	M	1375	$1.53	Acquired	109075	Direct
2021-12-14	Common Stock	S	1375	$45.88	Disposed	107700	Direct
2021-12-15	Common Stock	M	2750	$1.53	Acquired	110450	Direct
2021-12-15	Common Stock	S	2750	$50.00	Disposed	107700	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Stock Option (Right to Buy)	$1.53	M	1375	Disposed	2028-01-26	Common Stock (1375)	Direct
2021-12-15	Stock Option (Right to Buy)	$1.53	M	2750	Disposed	2028-01-26	Common Stock (2750)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.

F2: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.